top of page
Covid 19

Next Generation

 Viral Immunotherapies


3io Therapeutics is a Toronto-based biotechnology company focused on the development and commercialisation of the next generation of viral immunotherapies for cancer.

3io is currently developing a novel viral immunotherapy based on bovine herpesvirus type 1 (BHV-1), a virus that naturally infects cattle but is non-pathogenic in humans. 3io is committed to accelerating its development as a new therapeutic platform to improve treatment responses and outcomes for hard-to-treat cancers, including those with KRAS-mutations.

About us


BHV-1 is a novel viral immunotherapy with unexpected and

highly advantageous properties

Broad anti-tumor efficacy, including against KRAS-mutated tumors

Strong efficacy in preclinical studies

Immuno-stimulating mechanism of action

Efficacy does not rely on viral replication and direct tumor lysis

Potential for IV delivery

In vivo efficacy despite presence of neutralising antibodies

Excellent safety profile

Virus is non-pathogenic in humans

Potential as a monotherapy with minimal genetic engineering

Cassetted payload insertion is also possible

Boosts checkpoint inhibitor efficacy

Strong boost to efficacy seen in preclinical studies






Peng is a life sciences entrepreneur and investor with operational, legal, IP, financing and deal origination expertise developed at leading firms. Peng founded 3io Therapeutics in 2020 following roles in healthcare investment for both Fosun and CBC Group as a Managing Director. In 2015 Peng founded Novatio Ventures, a company specialising in the incubation of novel biopharma technologies. Prior to founding Novatio, Peng was Vice President, Business Development at DRI Capital, a leading life sciences private equity firm with more than US$3B of assets under management. Peng was responsible for biotech investment origination and acquisitions at DRI Capital and was a key contributor to the structuring and formation of Drug Royalty III, the firm's US$1.45B third managed fund. Prior to joining DRI Capital, Peng was Director and Senior Counsel at Amgen and served as the general counsel and a member of the senior management team of the company's Canadian affiliate. Previous to Amgen, Peng was Director of Legal Affairs at Teva, where he devised, implemented, and managed successful IP and regulatory strategies to realize first-to-market opportunities.


Peng began his career as an attorney at Gilbertʼs LLP, a biopharmaceutical focused boutique law firm, and then at Torys LLP, as a member of its life sciences and intellectual property practices. Peng holds an MSc in molecular biology and evolutionary ecology from the University of Toronto and a JD from Queenʼs University. He is fluent in Mandarin.



Chief Scientific Officer

Sandy is an accomplished researcher in innate immunity, genomics and oncology with both academic and industry leadership experience. Sandy was previously Scientific Associate at the Princess Margaret Cancer Centre and University Health Network where he studied the genomic and molecular pathology of lung cancers and worked on the development of novel immunotherapies for treating lung cancer and leukemia. In this capacity, Sandy co-invented prognostic, multi-gene classifiers for early-stage non-small cell lung cancer currently being commercialized by Helomics (Pittsburg, PA). Previously, Sandy was Director of Research at GeneNews, a Toronto-based biotechnology firm, where he was involved in the development of blood-based molecular assays for several cancers. Prior to this, Sandy was Assistant Professor at the Department of Laboratory Medicine and Pathobiology, University of Toronto where his lab was among the early adopters using genomic technologies to study human diseases including host immune responses to viral infections and cancer pathology.


Sandy completed his postdoctoral training in the Department of Cancer Biology at the Cleveland Clinic Foundation. He earned his PhD in the Department of Medical Genetics at the University of Toronto studying host responses to HIV infection, and his BSc from the same institution in microbiology.

Team-Ben Walker copy.jpg


Chief Business Officer

Ben is a global biopharma business development professional who has been strategic advisor to leading companies, institutions and start-ups. Ben previously ran business development for a U.S. technology accelerator, ACTUS Biotechnologies, where he played an integral role in strategic partnering for certain transdermal and tumor-targeting technologies licensed from UCSB and Sanford Burnham by its portfolio companies, Convoy and EnduRx. Since 2005, Ben has run a consulting firm, Nexanova Ltd, and worked on over 40 business development and licensing projects covering oncology, cardiovascular disease, neurology, dermatology and infectious diseases for leading bio-pharma clients in the U.S., Canada, U.K., Switzerland, China and Korea. He has also worked closely with universities and their spin-off companies, including University of Toronto, Western, HKUST, CUHK, SNU, and Yonsei.

Prior to entering the bio-pharma industry, Ben was China Business Development Manager for the animal nutrition division of Associated British Foods plc, where he specialized in acquisitions and set up two joint ventures in China. Ben holds an MA (Hons) degree in Chinese and Japanese from Edinburgh University and an MBA from Manchester Business School. He is fluent in Mandarin.


Please contact us to learn more about the BHV-1 technology and current partnering opportunities.

First Canadian Place

100 King Street West, Suite 5700

Toronto, ON M5X 1C7


+1 (339) 293 1288

Email us

Contact us
bottom of page